A new article was published in CPT: Pharmacometrics & Systems Pharmacology.

Sergey Gavrilov, Kirill Zhudenkov, Gabriel Helmlinger, James Dunyak, Kirill Peskov and Sergey Aksenov. Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Durvalumab. CPT: Pharmacometrics & Systems Pharmacology. 2020. https://doi.org/10.1002/psp4.12578

Joint Modeling approach was used to link tumor size and Neutrophil-to-Lymphocyte Ratio to overall survival of non-small cell lung cancer patients treated with Durvalumab. Multivariate nonlinear mixed-effects model was used to describe longitudinal behavior of biomarkers.